Editor's Note: Green and red arrows refer to intraday stock price movement.
NEW YORK (
CHANGE IN RATINGS
upgraded at Morgan Stanley from Equal-weight to Overweight. $32 price target. Company continues to execute on its growth strategy.
upgraded at Credit Suisse from Neutral to Outperform. $73 price target. Very strong orders.
upgraded at Oppenheimer from Perform to Outperform. $32 price target. Stock is attractive, following a recent pullback.
East West Bancorp
upgraded at FBR from Market Perform to Outperform. $23 price target. Stock is attractively valued, following a recent pullback.
upgraded at UBS from Neutral to Buy. $50 price target. Cost synergy story and leverage to power recovery.
upgraded at Jefferies to Buy. $52 price target. Estimates also upped, given recent Xyrem growth.
downgraded at Credit Suisse from Outperform to Neutral. $48 price target. Central theses played out.
upgraded at Credit Suisse from Neutral to Outperform. $110 price target. Stock should continue to deliver higher earnings.
upgraded at Baird from Neutral to Outperform. $92 price target. Company can continue to deliver solid growth over the coming years.
upgraded at Goldman from Neutral to Buy. Company was also added to the Conviction Buy list. $18 price target. Company is improving its position in the wireless market.
rated new Overweight at JP Morgan. $22 price target. Company has attractive exposure to urban markets.
upgraded at UBS from Neutral to Buy. $31.05 price target. VZW dividend larger than expected.
upgraded at Citigroup from Hold to Buy. $60 price target. Incivek should not disappoint.
End of report.
This article was written by a staff member of TheStreet.